find the ictal depressions, along the side BC oneiro-
phrenia, and along the side CA the schizo-affective psy-
chose. Investigating the families of patients suffering
from atypical schizophrenic illnesses, Mitsuda finds
psychotic states of a heterogeneous kind, typical and
atypical schizophrenias, affective illnesses and epilepsy,
a raised incidence of abnormal EEG rhythms, etc. Fam-
ily pedigrees may suggest dominance (e.g. with
affected individuals on only one side of the family),
recessivity (excess of abnormality only in the sibs), or
intermediate (e.g. neither of the above but with some
morbidit in sibs of parents or cousins). Classifying
schizophrenic patients according to their family his-
tories, one finds recovery or a periodic course predomi-
nating in the dominant group, chronic and deteriorating
case of illness with recessive family history. Second-
dary cases of psychosis found in the families of schizo-
phrenics tend to have a bad prognosis in the families
of nuclear schizophrenics, a good one in the families
of patients of the peripheral (atypical) groups. EEG
abnormalities were found in 67% of cases of the per-
ipheral group, as against 24% in the nuclear group; but
atrophic brain changes shown pneumoencephalographi-

cally were commoner in the nuclear than the peripheral
cases.

There is a wealth of information, gathered along
clinicogenetic lines by the investigation of parents and
sibs and twins, now made available to easy reference in
this book. Apart from the intensive work on the typical
psychoses, there are interesting studies on childhood
schizophrenia, involuntional depression, chronic alco-
holism, early childhood neuroses, and juvenile delin-
quency in twins.

ELIOT SLATER

A Neuropsychiatric and Genetical Investigation of
Acute Intermittent Porphyria. By Lennart
Wetterberg. (Pp. 87; illustrated + tables + appendix.)

Porphyria—A Royal Malady. Articles published or
commissioned by the British Medical Journal. By
Ida Macalpine, Richard Hunter, C. Rimington, John
Brooke, and Abe Goldberg. (Pp. vii + 68; illustrated.
12s. 6d.; $1.50.) London: British Medical Associa-
tion.

These two books offer a very sharp contrast, in their
aims, their achievements, and their presentation. It
is fair to say that only the first is a work of science;
the second is a speculative contribution to the study of
history, and should not be judged by the standards we apply
to the first.

The work by Wetterberg records the results of a well-
planned and thoroughly carried out investigation, which
adds considerably to our knowledge of acute intermittent
porphyria (AIP) (sometimes called the Swedish form of
the disorder). To begin with we have the mental
hospital enquête, which shows that 170 patients (9%) of
1907 mental hospital patients had an abnormally high
urinary excretion rate of porphobilinogen (PBG) or a
like-reacting substance; these patients were mostly on
phenothiazines. On thorough testing, 3 of these patients
were found to be true cases of AIP.

The next study was based on 225 members of 40 AIP
families, 197 sibs of patients, and 28 parents. Urinary
excretion both of PBG and of δ-aminolaevlyic acid
(ALA) was estimated and showed sharp differences be-
 tween the 89 unaffected individuals and the gene-
carriers, both latent (32) and manifest (76). The mean
excretion rate both of PBG and of ALA was a good deal
lower in the latent cases than in the manifest ones.
Genetical facts of great interest emerge. While the sex
ratio in the manifest cases shows, as generally the case,
a marked female preponderance, this is easily balanced
by a male preponderance in the latent (symptom-free)
cases. It is estimated that gene penetrance is complete
or nearly complete when measured by the PBG output
in the urine; 60% of gene carriers go on to be manifest
cases, 73% of females and 49% of males. Three sibs-
ships were found in which both parents were affected;
of the males 3 were manifest AIP cases, 4 were latent, and 3
were unaffected; of the females correspondingly 6, 3, and
3. In these sibships there were no abortions or mis-
carriages. This suggests that homozygotes for the gene
survive and are not clinically distinguishable from
heterozygotes. The disorder is not evenly distributed
geographically. Wetterberg estimates that in two
northern counties the AIP-gene frequency is about
1/1800, but only 1/40,000 for the rest of Sweden.

The main emphasis of the investigation was to answer
the question whether the difference between those
porphyrics who become mentally ill and those who do not
is related to non-genetical differences, to differences in
the genetic milieu independent of the AIP-gene, or to the
existence of more than one AIP-gene. To pursue this
inquiry 40 families were taken from a fairly complete
registration of AIP in Sweden, consisting of two equal
groups, one in which the propositi had AIP as well as
mental illness (A group), and the other (B group) in
which the propositi displayed the symptoms of AIP only.
No A:B phenotypical differences were found; but there
was significantly more mental illness in the A families
than in the B families, shown just as much in the rela-
tives free of AIP as in the latent and manifest gene-
carriers. The conclusion seems to be justified that this
association was due to the greater prevalence of inde-
pendently transmitted mental illness in the A families.
However, the presence of the AIP gene is correlated with
mental illness, and the gene appears to favour the mani-
festation of other predisposing agents. As a result of
clinical analysis, it was found possible to distinguish the
mental syndrome which could be specifically attributed
to AIP, as a phasic illness with slight to moderate depres-
sion, transitional confusional states, frequently visual
hallucinations, and neurological signs, central and peri-
pheral. The mental changes are in part due to tempo-
rary and reversible metabolic changes affecting the
nervous system, with some changes proving irreversible
and leaving focal lesions. The risk that attacks of AIP
will cause simultaneously CNS lesions so extensive or so
located as to cause mental illness is estimated as 1 in 6 to
1 in 3 patients. Wetterberg cannot support the suggestion that either schizophrenia-like or manic-depressive syndromes are predisposed to by AIP; nor does the presence of the gene tend to mental retardation.

Contrasting with the sober garb of Wetterberg’s report, the second book under review is a profusely illustrated glossy brochure in a purple cover. In it Dr. Macalpine, Dr. Hunter, and Professor Rimington put forward the interesting theory that the mental illness which affected George III was a form of porphyria. There are four contributions to this book, and in the first, by the two first-named authors, acute intermittent porphyria is offered as the true diagnosis of the King’s psychosis which has previously generally been taken to be manic-depressive. With admirable enterprise and industry the authors sought out and studied authenticated historical documents which have been passed over, it seems, by the historians. The case they make is a plausible one; it could perhaps have been improved if they had given us more detail of each of the attacks of illness separately. The psychiatrist will, however, be inclined to concede that the King’s mental symptoms do fit a psycho-organic syndrome better than a manic-depressive one. In the second chapter Professor Rimington joins the two psychiatric authors to show that two descendants of George II who have been traced can be definitely identified as porphyrins. The diagnosis for them and for George III is now varied to one of porphyria variegata, which is the South African and not the Swedish variant. In the third chapter a professional historian, Dr. John Brooke, acclaims the significance of the findings in the historical context; in the fourth Professor Goldberg gives a short and pithy statement, which could with benefit have been considerably expanded, on the porphyrins in clinical and metabolic aspects. All these contributions appeared originally as articles in the British Medical Journal or were commissioned by it. Since their appearance there has been a very lively debate in the correspondence columns of that journal and some searching re-examination of the evidence. This, on the whole, has not supported the hypothesis put forward by the authors.

This is certainly very entertaining, but one should remember a clinical diagnosis is one thing, and a historical diagnosis another. The latter cannot be substantiated in the way that the first can. It is not for the reviewer to express any opinion on a matter on which Professor Rimington and Professor Dent are unable to agree; but two comments may be made. From the point of view of the geneticist, the genealogical links, which join Mary Queen of Scots down the ages via George II and George III with the contestably porphyric representatives of the House of Hanover living today, offer little substance for the repeated diagnosis of porphyria. From the point of view of the psychiatrist, if the historian thinks that varying a psychiatric diagnosis from manic-depression to porphyria, from a ‘mental’ to a ‘physical’ malady, should cause him to review his entire view of the man’s personality, and to re-allot his estimates of praise- and blame-worthiness, then he mistakes the nature of psychiatric evidence.

**Eliot Slater**


In this book J. R. Smythies gives a further account of the tantalizing search for a biochemical lesion in schizophrenia, and in particular he reviews the present status of the methylation hypothesis. The methylation hypothesis is based on the twin facts that 3, 4-dihydroxyphenylethylylamine (dopamine) and related catecholamines are present in the mid-brain where they are thought to act as neurohumours, and that 3, 4, 5-trimethoxyphenylethylylamine (mescaline) produces a state not dissimilar to schizophrenia. Support was given to the hypothesis when it was shown that methylation of one of the hydroxy groups (at the 3 position) is the normal method of inactivating catecholamines at their site of action, and further evidence was provided by reports that 3, 4-dimethoxyphenylethylylamine (DMPE) was excreted in the urine of schizophrenics and not of normals (the pink spot). Disappointment came when it was shown that the pink spot was not in fact DMPE, and that in any case DMPE was inert in man in large doses. Now, however, it appears from work on structure/activity relations which Smythies and his colleagues are carrying out in Edinburgh that DMPE does in fact have a mescaline-like action if it is protected from amine oxidase by a methyl group on the terminal carbon of the side chain, as is the case with amphetamine. However, the body has not yet been shown to be capable of methylating catecholamines at the 4 position, and a methylated group here appears to be necessary (though not sufficient) for mescaline-like action. The author suggests that the 4-methylated derivatives may act by inhibiting the enzyme which normally methylates at the 3 position, thus leading to a rise in free catecholamines at the active sites.

Further tantalizing facts concern methylation at the other end of the aromatic amine molecules: that mammalian tissues are capable of N-methylating tryptamine, and that N-dimethyltryptamine is another member of the group of psychotomimetic drugs. Moreover, the N-methylating mechanism is strongly inhibited by chlorpromazine. These and other pieces of evidence for a disorder of methylation in schizophrenia are reviewed in a lucid style, and one is left with a strong sense of optimism that a practical application of the theory to therapy is not far away.

The author is assisted by Alec Coppen in a review of evidence concerning disorders of amines and electrolytes in affective disorders, in both of which studies some promising clues are being energetically followed up; and by Norman Kreitman in a review of epidemiological data. Outstanding in the latter is a clear discussion of work on the effect of the family as a possible predisposing factor in schizophrenia (double-bind, marital skew, etc.), and a description of the WHO ten-year programme of research into social psychiatry and epidemiology. The final chapter is a brave attempt to build a bridge between biological psychiatry and psychoanalysis.

**John Price**